Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma.

James T Topham¹, Haley M Beckmann², Joanna M Karasinska¹, Jonathan M Loree³, Jennifer J Knox⁴, Petr Kavan⁵, Derek Jonker⁶, Stephen Welch⁷, Felix Couture⁸, Frederic Lemay⁹, Mustapha Tehfe¹⁰, Mohammed Harb¹¹, Nathalie Aucoin¹², Yoo-Joung Ko¹³, Patricia A Tang¹⁴, Ravi Ramjeesingh¹⁵, Brandon M Meyers¹⁶, Christina A Kim¹⁷, Faiyaz Notta¹⁸, George Zogopoulos¹⁹, Steven Gallinger²⁰, Pan Du²¹, Shidong Jia²², Sharlene Gill²³, Dongsheng Tu²⁴, Chris J O'Callaghan²⁵, David F Schaeffer²⁶, Daniel J Renouf³

¹Pancreas Centre (Canada) Vancouver, British Columbia Canada.

²Pancreas Centre (Canada) Canada.

³BC Cancer Agency Vancouver, British Columbia Canada.

⁴Princess Margaret Cancer Foundation Toronto, ON Canada.

⁵Jewish General Hospital Canada.

⁶University of Ottawa Ottawa, ON Canada.

⁷Western Caspian University London, ON Canada.

⁸Hôtel-Dieu de Québec Canada.

⁹Université de Sherbrooke Sherbrooke, QC Canada.

¹⁰Fondation du CHUM Canada.

¹¹Moncton Hospital Canada.

¹²Hopital Cite-de-la-Sante Laval Canada.

¹³Sunnybrook Health Science Centre Toronto Canada.

¹⁴University of Calgary Calgary, AB Canada.

¹⁵Nova Scotia Cancer Centre Halifax, Nova Scotia Canada.

¹⁶Juravinski Cancer Centre Canada.

¹⁷CancerCare Manitoba Winnipeg, MB Canada.

¹⁸Princess Margaret Cancer Centre Canada.

¹⁹McGill University Health Centre Montreal, Quebec Canada.

²⁰University Health Network Canada.

²¹Predicine, Inc. Hayward, California United States.

²²Predicine, Inc. Hayward, CA United States.

²³BC Cancer Agency Vancouver, BC Canada.

²⁴Queen's University Kingston Canada.

²⁵Canadian Cancer Trials Group Kingston, Ontario Canada.

²⁶University of British Columbia Vancouver Canada.

PubMed DOI

Abstract

PURPOSE: Pre-existing and emerging molecular-targeted therapies have been identified for the treatment of pancreatic ductal adenocarcinoma (PDAC) and exemplify the need for incorporating tumor sequencing into routine clinical practice. Tumor profiling through circulating tumor DNA (ctDNA) represents an important opportunity in PDAC due to the aggressive nature of the disease. Circulating tumor fra…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.